REFERENCES
1. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and
national disease burden estimates of acute lower respiratory infections
due to respiratory syncytial virus in young children in 2015: a
systematic review and modelling study. The Lancet.2017;390:946-958.
2. Saravanos GL, Sheel M, Homaira N, et al. Respiratory syncytial
virus-associated hospitalisations in Australia, 2006–2015. Med J
Aust. 2019;210:447-453.
3. Kusel MM, Kebadze T, Johnston SL, Holt PG, Sly PD. Febrile
respiratory illnesses in infancy & atopy are risk factors for
persistent asthma & wheeze. Eur Respir J. 2012;39:876-882.
4. Jartti T, Gern JE. Role of viral infections in the development and
exacerbation of asthma in children. J Allergy Clin Immunol.2017;140:895-906.
5. Driscoll A, Arshad S, Bont L, et al. Does respiratory syncytial virus
lower respiratory illness in early life cause recurrent wheeze of early
childhood and asthma? Critical review of the evidence and guidance for
future studies from a World Health Organization-sponsored meeting.Vaccine. 2020;38:2435–2448.
6. Stensballe LG, Brunbjerg Simonsen J, Thomsen SF, et al. The causal
direction in the association between respiratory syncytial virus
hospitalization and asthma. J Allergy Clin Immunol.2009;123:131-137.e131.
7. Muňoz FM, Swamy GK, Hickman SP, et al. Safety and immunogenicity of a
respiratory syncytial virus fusion (F) protein nanoparticle vaccine in
healthy third-trimester pregnant women and their infants. J Infect
Dis. 2019;220:1802-1815.
8. Kong K, Krishnaswamy S, Giles M. Maternal vaccinations. Aust J
Gen Pract. 2020;49:630-635.
9. Madhi SA, Polack FP, Piedra PA, et al. Respiratory syncytial virus
vaccination during pregnancy and effects in infants. N Engl J
Med. 2020;383:426-439.
10. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory
syncytial virus monoclonal antibody, reduces hospitalization from
respiratory syncytial virus infection in high-risk infants. .Pediatrics. 1998;102:531-537.
11. Griffin MP, Yuan Y, Takas T, et al. Single-dose Nirsevimab for
prevention of RSV in preterm infants. N Engl J Med.2020;383:415-425.
12. Eick A, Karron R, Shaw J, et al. The role of neutralizing antibodies
in protection of American Indian infants against respiratory syncytial
virus disease. Pediatr Infect Dis J. 2008;27:207-212.
13. Chu HY, Steinhoff MC, Magaret A, et al. Respiratory syncytial virus
transplacental antibody transfer and kinetics in mother-infant pairs in
Bangladesh. J Infect Dis. 2014;210:1582-1589.
14. Saso A, Kampmann B. Vaccination against respiratory syncytial virus
in pregnancy: a suitable tool to combat global infant morbidity and
mortality? Lancet Infect Dis. 2016;16:e153-e163.
15. Edwards KM. Maternal antibodies and infant immune responses to
vaccines. Vaccine. 2015;33:6469-6472.
16. Trento A, Rodríguez-Fernández R, González-Sánchez MI, et al. The
complexity of antibody responses elicited against the respiratory
syncytial virus glycoproteins in hospitalized children younger than 2
years. Front Microbiol. 2017;8:1-12.
17. O’Brien KL, Chandran A, Weatherholtz R, et al. Efficacy of
motavizumab for the prevention of respiratory syncytial virus disease in
healthy Native American infants: a phase 3 randomised double-blind
placebo-controlled trial. Lancet Infect Dis. 2015;15:1398-1408.
18. Scheltema NM, Nibbelke EE, Pouw J, et al. Respiratory syncytial
virus prevention and asthma in healthy preterm infants: A randomised
controlled trial. Lancet Respir Med. 2018;6:257-264.
19. Nyiro JU, Kombe IK, Sande CJ, et al. Defining the vaccination window
for respiratory syncytial virus (RSV) using age-seroprevalence data for
children in Kilifi, Kenya. PLoS One. 2017;12:e0177803.
20. Scheltema NM, Kavelaars XM, Thorburn K, et al. Potential impact of
maternal vaccination on life-threatening respiratory syncytial virus
infection during infancy. Vaccine. 2018;36:4693-4700.
21. Kusel MM, de Klerk NH, Holt PG, Kebadze T, Johnston SL, Sly PD. Role
of respiratory viruses in acute upper and lower respiratory tract
illness in the first year of life: a birth cohort study. Pediatr
Infect Dis J. 2006;25:680-686.
22. Lambert SB, Ware RS, Cook AL, et al. Observational research in
childhood infectious diseases (ORChID): A dynamic birth cohort study.BMJ Open. 2012;2:e002134.
23. Sarna M, Lambert SB, Sloots TP, et al. Viruses causing lower
respiratory symptoms in young children: findings from the ORChID birth
cohort. Thorax. 2018;73:969-979.
24. Sarna M, Ware RS, Lambert SB, Sloots TP, Nissen MD, Grimwood K.
Timing of first respiratory virus detections in infants: A
community-based birth cohort study. J Infect Dis.2018;217:418-427.
25. Sly PD, Cormier SA, Lomnicki S, Harding JN, Grimwood K.
Environmentally persistent free radicals: Linking air pollution and poor
respiratory health? Am J Respir Crit Care Med.2019;200:1062-1063.
26. Sarna M, Ware RS, Sloots TP, Nissen MD, Grimwood K, Lambert SB. The
burden of community-managed acute respiratory infections in the first
2-years of life. Pediatr Pulmonol. 2016;51:1336-1346.
27. Takashima MD, Grimwood K, Sly PD, et al. Epidemiology of respiratory
syncytial virus in a community birth cohort of infants in the first 2
years of life. Eur J Pediatr. 2021;180:2125-2135.
28. Hallak LK, Collins PL, Knudson W, Peeples ME. Iduronic
acid-containing glycosaminoglycans on target cells are required for
efficient respiratory syncytial virus infection. Virology.2000;271:264-275.
29. Stensballe LG, Ravn H, Kristensen K, Meakins T, Aaby P, Simoes EA.
Seasonal variation of maternally derived respiratory syncytial virus
antibodies and association with infant hospitalizations for respiratory
syncytial virus. J Pediatr. 2009;154:296-298.
30. Piedra PA, Jewell AM, Cron SG, Atmar RL, Paul Glezen W. Correlates
of immunity to respiratory syncytial virus (RSV)
associated-hospitalization: establishment of minimum protective
threshold levels of serum neutralizing antibodies. Vaccine.2003;21:3479-3482.
31. Buchwald AG, Graham BS, Traore A, et al. Respiratory syncytial virus
(RSV) neutralizing antibodies at birth predict protection from RSV
illness in infants in the first 3 months of life. Clin Infect
Dis. 2020;ciaa648.
32. Nyiro JU, Sande CJ, Mutunga M, et al. Absence of association between
cord specific antibody levels and severe respiratory syncytial virus
(RSV) disease in early infants: A case control study from Coastal Kenya.PLoS One. 2016;11:e0166706.
33. Singleton RJ, Bruden D, Bulkow LR. Respiratory syncytial virus
season and hospitalizations in the Alaskan Yukon-Kuskokwim Delta.Pediatr Infect Dis J. 2007;26:S46-50.
34. Chu HY, Tielsch J, Katz J, et al. Transplacental transfer of
maternal respiratory syncytial virus (RSV) antibody and protection
against RSV disease in infants in rural Nepal. J Clin Virol.2017;95:90-95.
35. Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syncytial
virus neutralizing antibodies in cord blood, respiratory syncytial virus
hospitalization, and recurrent wheeze. J Allergy Clin Immunol.2009;123:398-403.
36. Habibi MS, Jozwik A, Makris S, et al. Impaired antibody-mediated
protection and defective IgA B-cell memory in experimental infection of
adults with respiratory syncytial virus. Am J Respir Crit Care
Med. 2015;191:1040-1049.
37. Brady MT, Byington CL, Davies HD, et al. Updated guidance for
Palivizumab prophylaxis among infants and young children at increased
risk of hospitalization for respiratory syncytial virus Infection.Pediatrics 2014;134:415-420.
38. Brunwasser SM, Snyder BM, Driscoll AJ, et al. Assessing the strength
of evidence for a causal effect of respiratory syncytial virus lower
respiratory tract infections on subsequent wheezing illness: a
systematic review and meta-analysis. Lancet Respir.2020;8:795-806.
39. National Asthma Council Australia. Australian Asthma Handbook,
Version 2.0. . In:2019: http://www.asthmahandbook.org.au. Accessed 23
April, 2020.
40. Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Respiratory
syncytial virus vaccines. Pediatr Infect Dis J.2019;38:e266-e269.